- Annual Report (Small Business Issuers) (10KSB)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-KSB

x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended September 30, 2008

o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-31469

M edical I nternational T echnology, I nc.

(Exact name of small business issuer as specified in its charter)

1872 Beaulac, Ville Saint-Laurent

Montreal, Quebec, Canada HR4 2E9

(514) 339-9355

Address of Principal Executive Offices

Colorado 84-1509950

(State of incorporation) (IRS Employer Identification #)

Securities registered under Section 12(b) of the Exchange Act:	None


Securities registered under Section 12(g) of the Exchange Act:	Common Stock, par value $.0001 per share

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports, and (2) has been subject to such filing requirements for the past 90 days. Yes o No x

Check if there is no disclosure of delinquent filers pursuant to Item 405 of Regulation S-B contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or informationstatements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. x

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12n-2 of the Exchange Act). YES o NO x

State issuer's revenues for its most recent fiscal year: $328,713

The aggregate market value of the voting and non-voting common equity held by non-affiliates as of September 30, 2008 is $0.02 (based on its reported last sale price by the OTC Pink Sheets).

The number of shares outstanding of the Registrant's common stock as of September 30, 2008 was 27,058,663.

Transitional Small Business Disclosure Format: YES o NO x

Medical International Technology, Inc.

Table of Contents

Description of Business	3

Description of Property	9

Legal Proceedings	9

Submission of Matters to a Vote of Security Holders	9

Market for Common Equity and Related Stockholder Matters	9

Recent Sales of Unregistered Securities	10

Equity Compensation Plan Information	10

Management's Discussion and Analysis or Plan of Operations	11

Financial Statements	14

Changes In / Disagreements with Accountants on Accounting/Financial Disclosure	29

Controls and Procedures	29

Other Information	30

Directors, Executive Officers, Promoters and Control Persons	30

Section 16(a) Beneficial Ownership Reporting Compliance	30

Code of Ethics	30

Executive Compensation	31

Security Ownership of Certain Beneficial Owners and Management	32

Certain Relationships and Related Transactions	33

Exhibits and Reports on Form 8-K	33

Principal Accountant Fees and Services	33

Signatures	34

Medical International Technology, Inc.

Item 1. Description of Business

Forward-Looking Statements

Certain statements concerning the Company's plans and intentions included herein may constitute forward-looking statements for purposes of the Securities Litigation Reform Act of 1995 for which the Company claims a safe harbor under that Act. There are a number of factors that may affect the future results of the Company, including, but not limited to, (a) the ability of the company to obtain additional funding for operations, (b) the continued availability of management to develop the business plan, (c) regulatory acceptance of our products in diverse localities and (d) successful development and market acceptance of the company’s products.

This periodic report may contain both historical facts and forward-looking statements. Any forward-looking statements involve risks and uncertainties, including, but not limited to, those mentioned above. Moreover, future revenue and margin trends cannot be reliably predicted.

General

Medical International Technology, Inc. was incorporated in the State of Colorado on July 19, 1999. The company has tree wholly-owned subsidiaries, Medical International Technologies Canada, Inc. (MIT Canada), a Canadian company, acquired in June of 2002, 3567940 Canada inc. a Canadian company, acquired in June of 2002 and ScanView, a Canadian company, acquired in June of 2007.

Medical International Technology, Inc. has authorized 100,000,000 shares of common stock, par value $.0001 and 3,000,000 shares of preferred stock, par value $.0001. Medical International Technology, Inc.'s common stock is traded on the NASD's Over-The-Counter Pink Sheets under the symbol "MDLH.PK".

The Company has a September 30 th fiscal year end.

Description of Business

Medical International Technology, Inc .(MIT) is based in Montreal, Canada; specializing in the research, development, marketing and sale of needle-free jet injector products designed for humans and animals, for single and mass injections. Needle-free jet injector technology and products provide advantages over traditional needle injection techniques and products, including; efficiency, handling security, biological waste elimination, and patient stress reduction.

ScanView has a unique, portable and battery operated ultrasound diagnostic medical devices, using a variety of probes for pathological and physiological evaluation of organs such as the heart, kidneys, liver, thyroid, uterus and ovaries. They serve equally well to detect kidney stones, diagnose pregnancy, visualize follicle development and carry out all other normal ultrasound diagnostic procedures.

Medical International Technology's intends to concentrate its activities in the medical and para-medical sectors, in particular, in the field of instrumentation. The company's strategy is to build a good order agenda for its different products and establish strategic alliances with different pharmaceutical companies and manufacturers to ensure good distribution channels for its products.

MIT Needle-free Jet injector Segment

The benefits of needle-free injection compared to needle injection, in particular with respect to the features of Medical International Technology products, can be summarized as follows:

(1)	Less tissue damage and less painful;

(2)	Simple, fast and effective;

(3)	Precise, reliable and safe;

(4)	Good absorption of liquids;

(5)	Prevents stress from traditional needle syringes and infections from contaminated needles;

(6)	Friendly to the environment (No biological waste);

(7)	Affordable and economical;

(8)	Efficient use of medication used.

-3-

Medical International Technology, Inc.

Target Products and Market

Animal Sector:

Medical International Technology, Inc. markets several Models of Agro-Jet Needle-Free injectors. The AGRO-JET Model MIT II, MIT III, MIT V, MIT VI, MIT X, MIT XI, MIT XII and MIT XIV. The AGRO-JET technology is a Low pressure, high performance, semi-automatic needle-free injector intended for the general use of the livestock market. The Models MIT II and MIT III is intended to target piglets of up to 20Kg. Piglets are one of the largest markets in the animal sector, because these animals require a large number of injections during their growth.

The Model MIT IIP and MIT XII, is manly targeting the world market for vaccination of Poultry, eliminating risks associated with cross contamination. The mass vaccination capabilities and reduced risks of cross contamination make these models suited to combat pandemic fears like Bird Flu and other global threats requiring mass vaccinations to prevent their spread.

The Agro-Jet Models MIT VI and X is a product intended for Pigs larger then 20Kg., Swine, Veal, Cattle, Beef Sheep, Equine and other livestock.

MIT V, MIT XI and MIT XIV are intended for sporadic injections with a reusable cartridge, of up to 5 ml.

Human Sector:

MED-JET is a similar product to the AGRO-JET Model MIT II intended for the mass vaccination of Human. MIT has received Health Canada approval and is in the process of obtaining FDA approval. MIT is marketing and selling its MED-JET in clinics in Canada and intends to market and sell in many other markets during the next fiscal year.

PRO-JET is a variation of the AGRO--JET products, in "pen-form", and intended for use in the human sector. The main customers targeted will be hospitals, clinics and individuals who must inject medications at home (diabetics and others). Needle-free injection technology, for humans even more than for animals, allows for painless injections and reduces the damage to skin and tissues, especially for people who must inject themselves frequently, such as:

(1)

Diabetics

(2)	Allergy Injections

(3)	Vitamins Injections

(4)	Growth Hormone Injections

(5)	Antibiotics Injections

(6)	Birth Control or Impotence Injections

(7)	Vaccines for Children

(8)	Antidote Vaccines for bee stings or snake bites, for example

(9)	Other neuroplegics

Medical International Technology, Inc. will target the diabetics market in fiscal year 2009. MIT will begin in the markets where our products are currently approved and continue our efforts in localities where approvals are pending. The market potential in this sector is extremely large because there are many diabetics throughout the world and many must inject insulin daily. A secondary market will be the allergy market. The allergy market includes a similar potential, as the number of individuals affected is quite large, as are the variety of allergies that may be involved. We are currently unable to access many of these markets due to the need for additional regulatory approvals in the localities for the various applications.

-4-

Medical International Technology, Inc.

Marketing and Distribution

MIT promotes its products in many countries including the United States of America. MIT is exerting every effort and using its resources to promote its products and to open markets for its technology. As we continue to market our products, we hope to gain broader acceptance of the needle-free injection technology.

MIT has adopted an approach with potential distributors; whereby, new distributors are allowed six months to test the market for the AGRO-JET. MIT is then able better evaluate potential distributors before signing long term Distribution Agreements. Where MIT may experience difficulties with distributors meeting their purchasing schedules, we will work with these distributors to assist them in developing their respective markets.

A new study published in March of 2007 has shown once more that the MED-JET-MBX has given excellent results anesthetizing patients who receive medical treatments which involve multiple injections such as for Hyperhydrosis (excessive sweating of the hands, feet and under arms) and BOTOX ® injections.

Product Development

Medical International Technologies is proceeding with the test requested earlier by the FDA, and is expecting to finalize the tests during 2009 fiscal year.

According to the International Sharps Injury Prevention Society (http://www.isips.org), it has been estimated that a contaminated sharp point accidentally sticks one out of every seven workers each and every year. The Center for Disease Control (CDC: http://www.cdc.gov/niosh/2000-108.html#5) estimates that there are 600,000 to 800,000 needle stick injuries per year in the U.S. alone, and many are not reported. More than 20 types of infectious agents have been transmitted through needlesticks, including hepatitis B and C, tuberculosis, syphilis, malaria, herpes, diphtheria, gonorrhea, typhus and Rocky Mountain spotted fever. The MED-JET will eliminate this risk to our health care professionals and create a safer workplace. Other advantages include its light weight (0.5 kg) and an excellent medication absorption rate. Additionally, the system has the ability to increase or decrease the volume and pressure of injection. This technology is unique to MIT’s MED-JET MBX Injector. The system is designed to allow for the injection of up to 600 individuals an hour.

Other advantages include its light weight (0.5 kg) and an excellent medication absorption rate. The system is designed to inject up to 600 individuals an hour. The MED-JET has patent protection and is approved for use in human medicine in Canada.

The approval process can be expensive and may take extended period of time. There can be no assurance that this system will receive approval from the FDA or if approved gain broad acceptance by the medical community or individual patients.

We previously announced that our needle free injection was chosen for testing in a study regarding the treatment of Hyperhydrosis. Dr. Antranik Benohanian MD, FRCPC Dermatologist at Saint Luc Hospital of The Montreal University Hospital Center, has begun tests of MIT’s human injectors in his Hyperhydrosis studies. In addition to the underarms, Hyprehydrosis often occurs in the palms, soles of the feet and even the face. Currently, treatments typically carried out by needle injections that must be repeated every 4-6 months, in excessive pain to patients. Many patients are reluctant to receive multiple injections in their hand and their face due to the pain associated with traditional injections.

The results have been published in two major associations. First was the American Academy of Dermatology and the second, in the British Journal of Dermatology. These publications provide strong evidence that the MED-JET Model MBX from Medical International Technology Inc., the only system in the world than can inject a minute volume of 0.02 ml up to 0.3 ml. fast, reliable and almost painless, in any part on the human body.

-5-

Medical International Technology, Inc.

Dr. Benohanian has continued using the MED-JET Model MBX for the treatment of Hyperhydrosis on over 100 patients; he is also using the MED-JET Model MBX for other treatments in the dermatology field.

Other Doctors in Montreal are also using MED-JET Model MBX and the MED-JET-H-II for injections of Lidocaine, Botox and Cortisone for different treatment, in Dermatology, minor surgery, Phisiatric and others.

MIT’s MED-JET ® MBX injector is expected to reduce patient’s pain and discomfort in these sensitive areas of the body that is caused by traditional needle injections. In addition, MIT’s needle free injector results in a less severe puncture since it has a volume of 0.02cc. Up-to. 3cc. It is important to be able to increase or decrease the volume and pressure of injection, based on the comfort level of the patient. This technology is unique to MIT’s MED-JET MBX Injector.

Hyperhydrosis is the medical term for excessive sweating. Millions of people worldwide suffer from this condition. In a recent survey (J Am Acad Dermato 2004:51(2): 241-258), an estimated 2.8% of the U.S. populations is affected by some form of this condition, with about a third of them describing their excessive sweating as barely tolerable or worse. The FDA approved BOTOX injections in July 2004 to treat severe Hyperhydrosis. Phase III clinical studies supporting the FDA approval show that 80% of patients experienced a 50% decrease in sweat production (source: Allergan, Inc. July 20, 2004 press release).

We previously announced that the Med Jet(r) Needle Free MBX Model Injector and its advantages in the treatment of palmar hyperhidrosis had been featured in the June 2005 edition of the Journal of the American Academy of Dermatology (JAAD). The article is titled: ''Use of needle-free anesthesia in the treatment of palmar hyperhidrosis with botulinum “A toxin.'' The Journal is dedicated to the clinical and continuing education needs of the entire dermatologist community and is internationally known as the leading journal in the field. The Journal ranks in the top 4.3% of the 5,684 scientific journals most frequently cited (2000 Science Citation Index).

MIT’s development of the MED-JET MBX injector is further encouraged by the increased awareness of the Hyperhydrossis condition and available treatments. We note mainstream discussion of this condition and the BOTOX injection treatment in the September 2005 issue of “Shape” magazine in the Beauty Q&A section “stop SWEATING” which includes a testimonial of the procedure.

Scan View; Ultra Sound Segment

On December 19, 2005 the Board of MIT adopted a resolution stating “MIT will acquire all of the issued and outstanding shares of 9139-2449 Quebec Inc operating under the name “Scanview” for 2,500,000 restricted common shares of MIT".

On December 22, 2005 we announced that MIT would proceed with the ScanView acquisition. Scanview is a portable ultrasound technology and manufacturing company in Montreal, Quebec, Canada. Scanview was formed in 2003 to develop, manufacture and market different models of Real Time Ultrasound Scanners, for Animal and Human applications.

On June 11 2007, the Board of Director of MIT signed an agreement with 9162-9725 Quebec Inc a Quebec private company, to purchase all of the issued and outstanding shares of 9139-2449 Quebec Inc. (SCNAVIEW) common stock, for a total of 2,500,000 Common shares of MIT. Following the signing of the agreement MIT issued to 9162-9725 Quebec Inc. a total of 2,500,000 Common shares of MIT.

ScanView is a private Canadian company owned by Karim Menassa, our CEO and Director, owning 55% of Scanview, Michel Bayouk, our CFO and Director, owning 10% of Scanview and three other unrelated shareholders.

-6-

Medical International Technology, Inc.

Products

The “SCAN VIEW I”, “SCANVIEW 100-S” and “SCANVIEW 100-SBF” ultra sound scanners, for animal and human applications are the first models introduced to the market. New models for human and animal applications will be available in 2008.

These portable ultrasound diagnostic medical devices use a variety of probes for pathological and physiological evaluation of organs such as the heart, kidneys, liver, thyroid, uterus and ovaries. They serve equally well to detect kidney stones, diagnose pregnancy, visualize follicle development and carry out all other normal ultrasound diagnostic procedures.

The “SCANVIEW I” and “SCANVIEW 100-S” and “SCANVIEW 100-SBF” are battery operated and power supplied, using state of the art and, latest microelectronics components. The Scanners have a built-in 5-inch, LCD Colour monitor, and an integrated PC base video processor, which allows images and Cine-loop to be transferred to a PC, reproduced and printed at any time.

Market

The Veterinary Market

There are some 795,000 cattle and pig farms around the world to which the Scan View can be marketed.

Pork is the most frequently consumed meat in the world, with a consumption rate of 40%. The five largest pork producers in the world are, in order of size, China, United States, Germany, Spain and France. Canada is in thirteenth place, just behind Japan.

The American pork industry is a vital part of the U.S. economy, generating many billions of dollars. In 1995, the United States sold more than 103 million hogs, for $10.6 billion, or 11.6% of total agricultural sales. In 1997, the country exported more than $1 billion in pork products.

In 1997, there were some 138,690-pig farms in the United States. The trend is for these farms to get bigger: more than 80% of pigs are raised on farms that produce more than 1,000 pigs per year. Farms producing 50,000 pigs and more per year substantially increased their market share, rising from 7% in 1988 to 37% in 1997.

Sows have an average of 6 litters. Each sow gives birth on average to 16 piglets per year. All sows must be checked for pregnancy in each breeding cycle.

The Pregnancy diagnosis and back fat measurements program is clearly important in this industry and accounts for between 30 and 50% of the total veterinary care.

The Human Market

While the “SCANVIEW I” was originally conceived in response to the needs of veterinary medicine, SCANVIEW INC. has found an excellent market niche in the human market place.

The new “SCANVIEW 100-S” for Human applications was introduced at the end of 2006; the new ultrasound scanner is for the General Practitioner Clinic industry.

Other potential markets for the “SCANVIEW 100-S” are First aid workers in both urban and remote areas, mobile and small clinics around the world, and field hospitals for armed forces, to name but a few.

There are over eight hundred (800) clinics in Canada and several thousand in the United States, which are the target market.

-7-

Medical International Technology, Inc.

Scanview’s latest model the “SCANVIEW 100-SBF” which is designed for Human body fat measurements and introduced at the end of 2006, targeting the booming cosmetic market (plastic surgeon, liposuction, and many other niche markets) where baby boomers who seek a rejuvenated appearance spending increasing amounts to have a younger look. Scanview’s objective in the short term is to create a niche market for its “SCANVIEW 100-SBF” in this market and to establish itself as a leader in state-of-the-art ultrasound scanner in the world.

Competition

There are several companies producing ultrasound scanners throughout the world, developed for the human sector. There are only five companies that produce scanners for the Veterinarian market.

Scanview is believes that it has surpassed its competition with its “SCANVIEW I”, “SCANVIEW 100-S” and “SCANVIEW 100-SBF” by having higher performance and better ergonomic design.

Marketing

Scanview will expand its distribution network for our products. As discussed, we will serve two major markets - both human and veterinary medicine. As each market requires a different approach and has specific individual needs, the marketing strategy developed for each of these markets is based on SCANVIEW INC. Marketing management experience and market feedback.

The foundation of our marketing strategy is based on customer training. Therefore, each step of our sales and promotional program is geared toward the specific needs that have been identified for each target market. The objective is to carefully choose local, influential, successful distributors in selected territories and optimize market awareness in order to achieve maximum sales results.

MIT is continually researching and developing its products to the market needs.

Patents and Trademarks

MIT has obtained trademark registration in United States on the use of AGRO-JET (Reg. No. 2,712,089) and MED-JET (Reg. No. 2,798,613).

Regulation and Approvals

MIT produces products that may require various approvals by government agencies in the locals in which they are used. These regulations or approvals vary greatly depending upon the way our products are used. We may not have the required approvals for various applications of our products in those localities. We continue to seek approvals for various applications of our products but the costs associated with achieving such approvals may exceed our available resources or be commercially impracticable.

We have received full certification for our Quality Management System granted under the International Organization for Standardization's ISO: 9001:2000. This includes Certification for the “Canadian Medical Device Conformity Assessment System” (CMDCAS), for devices to be licensed by HEALTH CANADA. The company plans to aggressively market the MED-JET for human use for mass-inoculation. The company feels that Canadian and other world markets can benefit greatly from the MED-JET. By using the MED-JET, health officials have an alternative delivery method that is safer and faster than the traditional needle.

Medical International Technologies, Inc has received full certification granted under the International Organization for Standardization, as well as the Canadian Medical Device Conformity Assessment System, for devices to be licensed by HEALTH CANADA. These certifications allow MIT to market the Med-Jet Needle-Free Injector for human use in all countries other than the U.S., at this point. The Med-Jet injector has been submitted for FDA approval, which, if accepted, will allow MIT to sell the Med-Jet in the United States, making it a truly worldwide system.

-8-

Medical International Technology, Inc.

The Company is still working to complete FDA filings for the use of the Med-Jet for injecting anesthesia in a variety of situations and the use of the Med-Jet-H, for mass vaccination in case of a pandemic, such as Avian Influenza, Polio, Tuberculosis, or Malaria.

Medical International Technologies is proceeding with the test requested earlier by the FDA, and is expecting to finalize the tests during 2008 fiscal year.

Australian Wool Innovation Limited (AWI) is in the final stage of negotiation with a Pharmaceutical partner for the production and Distribution of the various compounds that will be used with MIT Agro-jet.

MIT is expecting to negotiate with the Pharmaceutical partner and sign a Supply agreement as soon as the agreement between AWI and the Pharmaceutical Company is signed and sealed.

There can be no assurance that this system will receive approval from the respective agencies.

Employees

Currently, the company has six employees, the President and Chief Executive Officer of the company, and other employees. As operations are expanded additional employees will be required.

Item 2. Description of Property

Medical International Technology, Inc. currently leases its office under an operating lease that expires October 31, 2009. These offices are a 5,200 square foot industrial facility in Montreal Canada. Facilities include various machine tools and test systems for prototyping and light production. The annual lease expense for the facilities for the year ending September 30, 2008 was $29,000. The current lease rate is $29,000 annually.

Item 3. Legal Proceedings

The company is or was engaged in the following Legal Proceedings:

(a) Ratha Yip vs. MEDICAL INTERNATIONAL TECHNOLOGIES (MIT CANADA) INC. and Karim Ménassa, small claim court file 500-32-104717-071, for unpaid accounts to the amount of $7 000.00 CDN. The plaintiff, Ratha Yip, was the designer for the products of the company. The company believes it should not be involved in this dispute because that the plaintiff did not execute the services for which he was engaged, and intends to vigorously defend itself.

Item 4. Submission of Matters to a Vote of Security Holders

No matters were submitted to a vote of security holders in the fourth quarter of the year ending September 30, 2008.

Item 5. Market for Common Equity and Related Stockholder Matters

Market Information

Medical International Technology, Inc. common stock is currently listed on Pink Sheets under the symbol “MDLH.PK” and was formerly listed on the NASD Over-The-Counter Bulletin Board under the symbol “MDLH”, and prior to November 21, 2005 "MDIR". The following table sets forth, for the periods indicated, the last sale prices for the Common Stock as reported by the Pink Sheets.

-9-

Medical International Technology, Inc.

	High		Low
Date
September 2008	$	0.02	$	0.02
June 2008	$	0.02	$	0.02
March 2008	$	0.02	$	0.02
December 2007	$	0.02	$	0.02
September 2007	$	0.08	$	0.02
June 2007		0.08		0.05
March 2007		0.1		0.05
December 2006		0.3		0.15
September 2006		0.66		0.51
June 2006		0.61		0.45
March 2006		1.55		1.19
December 2005		1.1		0.7

Holders

Medical International Technology had 27,058,663 shares of common stock issued and outstanding as of September 30, 2008, which were held by approximately 71 shareholders and an undetermined number of shareholders holding common shares in street name (CEDE&CO).

Options

The Company has no option agreements outstanding as of September 30, 2008.

Private Placements

The Company has not completed or offered any private placement agreements in during fiscal 2008.

Preferred Stock

As of September 30, 2008 there was no preferred stock outstanding. Dividend features and voting rights are at the discretion of the Board of Directors without the requirement of shareholder approval.

Recent Sales of Unregistered Securities

There were no sales of unregistered securities during fiscal 2008.

Equity Compensation Plan Information

The Company has a stock compensation plan, as filed on Form S-8 on September 28, 2006, under which directors are authorized to grant incentive stock options, to a maximum of one million (1,000,000) shares, to directors, employees and consultants of the Company. The plan provides both for the direct award or sale of shares and for the grant of options to purchase shares.

The following table provides information as of September 30, 2008 regarding compensation plans (including individual compensation arrangements) under which equity securities are authorized for issuance:

-10-

Medical International Technology, Inc.

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted-average exercise price of outstanding options, warrants and rights	Number of securities available for future issuance under equity compensation plans (excluding securities shown in first column)
Equity compensation plans approved by shareholders (1)(2)	0	$0.00	0
Equity compensation plans not approved by shareholders (1)(3)	0	$0.00	321,700
Total	0	$0.00	321,700

(1) Consists of shares of our common stock issued or remaining available for issuance under our stock compensation plan.

(2) Approved by shareholders of Medical International Technology, Inc.

(3) The total common stock issued from the maximum 1,000,000 shares authorized under the stock compensation plan as of September 30, 2008 was 678,300 shares.

Dividend Policy

Medical International Technology, Inc. has not paid a cash dividend on its common stock in the past 12 months. The company does not anticipate paying any cash dividends on its common stock in the next 12-month period. Management anticipates that earnings, if any, will be retained to fund the company's working capital needs and the expansion of its business. The payment of any dividends is at the discretion of the Board of Directors.

Item 6. Management's Discussion and Analysis or Plan of Operations

When used in this Form 10-KSB and in future filings by the company with the Commission, statements identified by the words “believe”, “positioned”, “estimate”, “project”, “target”, “continue”, “will”, “intend”, “expect”, “future”, “anticipates”, and similar expressions express management’s present belief, expectations or intentions regarding the company’s future performance within the meaning of the Private Securities Litigation Reform Act of 1995. The safe harbor in the Private Securities Litigation Act of 1995 does not apply to statements made in this document. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical earnings and those presently anticipated or projected. The company has no obligations to publicly release the result of any revisions which may be made to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.

Overview

The following discussions and analysis should be read in conjunction with the Company’s consolidated financial statements and the notes presented following the financial statements. The discussion of results, causes and trends should not be construed to imply any conclusion that such results or trends will necessarily continue in the future.

Medical International Technology, Inc. (MIT) is receiving revenues from sales. The company has maintained operations from these revenues and through equity and debt financing. The company has been dependent on advances from related parties to maintain operations. There are no agreements, assurances or commitments to continue providing these advances. Products are currently developed, assembled and shipped from our facility. Component manufacturing is subcontracted to various suppliers and machine shops.

Distribution agreements are being sought worldwide for the Company’s products.

Critical Accounting Policies

The accompanying discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. These estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We base our estimates and judgments on historical experience and all available information. However, future events are subject to change, and the best estimates and judgments routinely require adjustment. US GAAP requires us to make estimates and judgments in several areas, including those related to recording various accruals, income taxes, the useful lives of long-lived assets, such as property and equipment and intangible assets, and potential losses from contingencies and litigation. We believe the policies discussed below are the most critical to our financial statements because they are affected significantly by management’s judgments, assumptions and estimates.

-11-

Medical International Technology, Inc.

Foreign Currency Translations

The Company operates out of its offices in Montreal, Canada and maintains its books and records in Canadian Dollars. The financial statements herein have been converted into U.S. Dollars. Balance sheet accounts, other than property and equipment, have been translated at exchange rates in effect at the end of the year. Property and equipment is converted at the exchange rate in effect at the date of purchase. Income statement accounts have been translated at average exchange rates for the year. Translation gains and losses are included as a separate component of stockholders’ equity.

Income Taxes

The Company accounts for income taxes using the asset and liability method described on SFAS No. 109, “Accounting For Income Taxes”, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of Water’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

New Accounting Pronouncements

In December 2007, the FASB issued SFAS 141 (revised 2007), "Business Combinations". SFAS 141R is a revision to SFAS 141 and includes substantial changes to the acquisition method used to account for business combinations (formerly the "purchase accounting" method), including broadening the definition of a business, as well as revisions to accounting methods for contingent consideration and other contingencies related to the acquired business, accounting for transaction costs, and accounting for adjustments to provisional amounts recorded in connection with acquisitions. SFAS 141R retains the fundamental requirement of SFAS 141 that the acquisition method of accounting be used for all business combinations and for an acquirer to be identified for each business combination. SFAS 141R is effective for periods beginning on or after December 15, 2008, and will apply to all business combinations occurring after the effective date. The Company is currently evaluating the potential impact of SFAS 141R on its consolidated financial statements.

In December 2007, the FASB issued SFAS 160, "Non-controlling Interests in Consolidated Financial Statements - an amendment of Accounting Research Bulletin No. 51, Consolidated Financial Statements" ("ARB 51"). This Statement amends ARB 51 to establish new standards that will govern the (1) accounting for and reporting of non-controlling interests in partially owned consolidated subsidiaries and (2) the loss of control of subsidiaries. Non-controlling interest will be reported as part of equity in the consolidated financial statements. Losses will be allocated to the non-controlling interest, and, if control is maintained, changes in ownership interests will be treated as equity transactions. Upon a loss of control, any gain or loss on the interest sold will be recognized in earnings. SFAS 160 is effective for periods beginning after December 15, 2008. The Company is currently evaluating the potential impacts of SFAS 160 on its consolidated results of operations and financial position.

In March 2008, the FASB issued ASAS No. 161, "Disclosure about Derivative Instruments and Hedging Activities, an amendment of FASB Statement No. 133" (SFAS 161), which establishes, among other things, the disclosure requirements for derivative instruments and hedging activities. SFAS 161 requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of and gains and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements. SFAS 161 is effective for fiscal periods and interim period beginning after November 15, 2008. The Company does not expect the adoption of SFAS 161 to have a material impact on its consolidated results of operations, financial position or cash flows.

-12-

Medical International Technology, Inc.

Financial Condition and Results of Operations

During the fiscal year ending September 30, 2008 the Company experienced a net loss of $2,361,882, primarily comprised of selling, general and administrative expenses of $656,059 and research and development costs of $1,802,085. Included in research and development costs are expenses of $1,800,000 related to the Company’s research and development contract with Idee International R&D, Inc., an affiliated entity. For the prior fiscal year 2007 the Company experienced a net loss of $898,376 where selling, general and administrative expenses totaled $830,363. And research and development costs were $134,294.

Net comprehensive loss, after adjustment for foreign currency translation, for fiscal year 2008 was $2,632,393.

For the twelve-months ended September 30, 2008 the Company experienced a decrease in sales of $9,813 compared to sales for the prior year. Gross profit for the twelve-months ended September 30, 2008 was $97,243 or approximately 30% of sales as compared to $216,652, or 64%. Costs of sales continue to be increased by the need to customize many of the items ordered to fit the particular needs of clients utilizing our products in new applications.

Liquidity and Capital Resources

During the fiscal year ending September 30, 2008 the Company’s cash position decreased by $92,702. Net cash provided by operating activities was $521,257, resulting primarily from increases in related party payables and deferred income. Net cash used by financing activities was $332,014, resulting primarily from debt repayments of $282,318. Net cash used by investing activities was $4,648, resulting entirely from capital asset additions. The effect of exchange rates on cash during fiscal 2008 resulted in a decrease in cash values of $277,297.

The Company has reported a net liability position of $2,629,455 and has accumulated operation losses since inception of $9,333,413, which raises substantial doubt about the Company’s ability to continue as a going concern. The continuation of the Company is dependent upon the continuing financial support of creditors and stockholders and upon obtaining the capital requirements for the continuing operations of the Company. Management believes actions planned and presently being taken provides the opportunity for the Company to continue as a going concern.

Medical International Technology, Inc. expects that revenues from existing and developing sales may not meet its liquidity requirements for the next 12-month period at its current level of operations. The company has been dependent on advances from related parties to maintain operations. There are no agreements, assurances or commitments to continue providing these advances. The company continues to rely on management to develop the business and work to develop sales. Management has and may continue to supplement cash flows from sales with additional equity and debt financing. Substantially, expanded operations are expected to require additional capital, either from a future offering of equity or the company pursuing other methods of financing, as appropriate.

Management Plan of Operations

Medical International Technology, Inc. is based in Montreal, Canada; specializing in the research, development, marketing and sale of needle-free jet injector products designed for humans and animals, for single and mass injections. Needle-free jet injector technology and products provide advantages over traditional needle injection techniques and products, including; efficiency, handling security, biological waste elimination, and patient stress reduction.

Medical International Technology's intends to concentrate its activities in the medical and veterinary sectors, in particular, in the field of equipment and instrumentation. The company's strategy is to build good, reliable and cost effective products, seek and establish strategic alliances with different pharmaceutical companies and manufacturers to ensure good distribution channels for its products.

MIT is continually researching and developing its products to the market needs.

Medical International Technology, Inc. will continue to seek additional funding to expand operations and develop sales revenue to a volume sufficient to sustain operations.

-13-

Medical International Technology, Inc.

Item 7. Financial Statements

Medical International Technology, Inc.

Financial Statements

Contents

	Page
Report of Independent Registered Public Accounting Firm	15
Financial Statements
Consolidated Balance Sheet	16
Consolidated Statements of Operations	17
Consolidated Statements of Comprehensive Loss	18
Consolidated Statement of Stockholders’ (Deficit)	19
Consolidated Statements of Cash Flows	20
Notes to Consolidated Financial Statements	21

-14-

Report of Independent Registered Public Accounting Firm

To The Board of Directors and Stockholders of

Medical International Technology, Inc.

We have audited the accompanying consolidated balance sheet of Medical International Technology, Inc. and subsidiaries as of September 30, 2008 and 2007, and the related consolidated statements of operations, comprehensive loss, stockholders’ deficit, and cash flows for the years then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audits in accordance with generally accepted auditing standards as established by the U.S. Auditing Standards Board and in accordance with the auditing standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the 2008 and 2007 consolidated financial statements referred to above present fairly, in all material respects, the financial position of Medical International Technology, Inc. and subsidiaries as of September 30, 2008 and 2007, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has a working capital deficiency. Those conditions raise substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ PS STEPHENSON & CO., P.C.

Wharton, Texas

November 21, 2008

-15-

MEDICAL INTERNATIONAL TECHNOLOGY

CONSOLIDATED BALANCE SHEETS

	September 30,
	2008			2007
Assets

Current assets
Cash and cash equivalents	$	94,834		$	187,536
Accounts receivable		-			6,937
Inventories		169,459			194,826
Research credit receivable		-			127,718
Prepaid expenses		3,565			2,764
Total current assets		267,858			519,781
Property and Equipment
Tooling and machinery		229,823			225,175
Furniture and office equipment		133,014			133,014
Leasehold improvements		22,163			22,163
Total property and equipment		385,000			380,352
Less accumulated depreciation		(299,500	)		(245,536	)
Total property and equipment, net		85,500			134,816

Patents (net of accumulated amortization of $1,398 and $932)		632			1,098

Total assets	$	353,990		$	655,695

Liabilities and Stockholder's Equity (Deficit)

Current liabilities
Deferred income	$	1,353,782		$	7,494
Accounts payable and accrued expenses		90,245			235,102
Amounts due to related parties		1,524,321			63,050
Loans payable – related parties		-			49,696
Current portion of long-term debts		8,237			283,154
Total current liabilities		2,976,585			638,496
Long-Term Debts		6,860			14,261
Total liabilities		2,983,445			652,757

Stockholder's Equity (Deficit)
Preferred stock, $.0001 par value; 3,000,000 shares authorized;
No issued and outstanding shares.		-			-
Common stock, $.0001 par value; 100,000,000 shares authorized;
27,058,663 and 27,058,663 issued and outstanding, respectively		2,706			2,706
Additional paid-in capital		6,804,339			6,804,339
Accumulated deficit		(9,333,413	)		(6,971,531	)
Other comprehensive income (loss)		(103,087	)		167,424
Total Stockholder's Equity (Deficit)		(2,629,455	)		2,938

Total Liabilities and Stockholder's Equity (Deficit)	$	353,990		$	655,695

The accompanying notes are an integral part of these consolidated financial statements.

-16-

MEDICAL INTERNATIONAL TECHNOLOGY

CONSOLIDATED STATEMENTS OF OPERATIONS

	Years Ended September 30,
	2008			2007


Sales	$	328,713		$	338,526
Cost of sales		231,470			121,874
Gross profit		97,243			216,652

Operating expenses
Research and development costs		1,802,085			134,294
Selling, general and administrative expenses		656,059			830,363
Total operating expenses		2,458,144			964,657
Operating income (loss)		(2,360,901	)		(748,005	)

Other income (expense):
Goodwill impairment charge		-			(131,382	)
Interest income		16,798			6,474
Interest expense		(17,779	)		(25,463	)
Total other income (expense)		(981	)		(150,371	)

Income (loss) before provision for income taxes		(2,361,882	)		(898,376	)

Provision for (benefit from) income taxes		-			-

Net loss	$	(2,361,882	)	$	(898,376	)

Net loss per common share	$	(0.09	)	$	(0.03	)
Weighted average common shares
outstanding - basic and diluted		27,058,663			27,058,663

The accompanying notes are an integral part of these consolidated financial statements.

-17-

MEDICAL INTERNATIONAL TECHNOLOGY

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Years Ended September 30,
	2008			2007

Net loss	$	(2,361,882	)	$	(898,376	)
Other comprehensive income (loss)
Foreign currency translation adjustment		(270,511	)		167,424

Comprehensive loss	$	(2,632,393	)	$	(730,952	)

The accompanying notes are an integral part of these consolidated financial statements.

-18-

MEDICAL INTERNATIONAL TECHNOLOGY

CONSOLIDATED STATEMENT OF STOCKHOLDERS' (DEFICIT)

					Additional
	Common Stock				Paid-in		Accumulated
	Shares		Amount		Capital		Deficit

Balances - September 30, 2006		10,867,737	$	1,086	$	5,786,600	$	(6,073,155	)

Common shares issued for debts		3,920,593		392		217,811
Common shares issued for services		9,498,333		951		560,185
Common shares issued in private placements		272,000		27		64,993
Common shares issued for the acquisition of Scanview		2,500,000		250		174,750
Net loss for the year ended September 30, 2007								(898,376	)

Balances - September 30, 2007		27,058,663		2,706		6,804,339		(6,971,531	)

Net loss for the year ended September 30, 2008								(2,361,882	)

Balances - September 30, 2008		27,058,663	$	2,706	$	6,804,339	$	(9,333,413	)

The accompanying notes are an integral part of these consolidated financial statements.

-19-

MEDICAL INTERNATIONAL TECHNOLOGY

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Years Ended September 30,
	2008			2007

Cash flows from operating activities:
Net loss	$	(2,361,882	)	$	(898,376	)
Adjustments to reconcile net loss to net cash
provided by (used in) operating activities:
Depreciation expense		53,963			46,446
Amortization expense		466			466
Common stock issued for debts and services		-			779,340
Common stock issued for Scanview acquisition		-			175,000
Changes in:
Accounts receivable		6,937			12,307
Research credit receivable		127,718			54,912
Inventories		25,367			(116,004	)
Prepaid expenses		(801	)		2,604
Accounts payable and accrued liabilities		(159,805	)		(185,254	)
Related party payables		1,476,219			63,050
Deferred income		1,353,075			(50,064	)
Net cash used by operating activities		521,257			(115,573	)

Cash flows from investing activities:
Tooling and machinery		(4,648	)		(73,642	)
Net cash used by investing activities		(4,648	)		(73,642	)

Cash flows from financing activities:
Proceeds from issuance of stock, net		-			65,020
Reduction in amounts due to related parties		(49,696	)		(221,844	)
Issuance of notes payable		-			347,111
Repayment on notes payable		(282,318	)		-
Net cash provided from financing activities		(332,014	)		190,287

Effect of exchange rates on cash		(277,297	)		13,544

Increase (decrease) in cash		(92,702	)		184,616
Cash, beginning of period		187,536			2920
Cash, end of period	$	94,834		$	187,536

Supplemental disclosure of cash flow information:
Cash paid for interest	$	17,779		$	25,463
Cash paid for federal income taxes	$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements.

-20-

Medical International Technology, Inc.

Note 1 – Business Activities and Related Risks

Medical International Technology, Inc. (the "Company") was incorporated in Colorado on July 19, 1999, under the name, Posterally.com, Inc. The Company filed an amendment to its articles of incorporation on September 24, 2002 changing its name to Medical International Technology, Inc.

The Company is in the business of developing and manufacturing a needle free device for use in injecting medicine and supplements for human and animal use.

Going Concern:

The Company has incurred net losses aggregating $4,769,891 during the three years ended June 30, 2008. In addition, the Company has a working capital deficiency of $2,708,727 and a stockholder’s deficiency of $2,629,455 at September 30, 2008. These factors, amongst others, raise substantial doubt about the Company’s ability to continue as a going concern.

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing stockholders.

The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

The Company has developed a plan to address liquidity in the following ways:

●	To raise capital through the sale or exercise of equity securities
●	Increase revenue through the sale of needle free devices and related products

Note 2 – Summary of Significant Accounting Policies

Principles of consolidation

The accompanying financial statements include the accounts and transactions of Medical International Technology, Inc. and its wholly owned subsidiaries, Medical International Technologies (MIT Canada) Inc. and 9139-2449 Quebec Inc. (dba Scanview), which was acquired by the Company on June 11, 2007 (Note 6). Accordingly, the accompanying financial statements only include the results of operations of Scanview since June 11, 2007. Intercompany transactions and balances have been eliminated in consolidation.

Foreign Currency Translations

Cash and Cash Equivalents

For purpose of the statements of cash flows, the Company considers cash and cash equivalents to include cash on hand, amounts due to banks and any other highly liquid investments with maturities of three months or less.

-21-

Medical International Technology, Inc.

Allowance for Doubtful Accounts

The allowance for doubtful accounts on accounts receivable is charged to income in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. At each balance sheet date, the Company evaluates its ending inventories for excess quantities and obsolescence. This evaluation includes an analysis of sales levels by product type. Among other factors, the Company considers historical and forecasted demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining the net realizable value of the inventory. Provisions are made to reduce excess or obsolete inventories to their estimated net realizable values. Once established, write-downs are considered permanent adjustments to the cost basis of the excess or obsolete inventories.

Property and Equipment

The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes and on the declining balance method for income tax reporting purposes. Depreciation expense for the year ended September 30, 2008 and 2007 were $53,963 and $46,466, respectively.

Long-Lived Assets

In August 2001, SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," was issued establishing new rules and clarifying implementation issues with SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be disposed of, "by allowing a probability-weighted cash flow estimation approach to measure the impairment loss of a long-lived asset. The statement also established new standards for accounting for discontinued operations. Transactions that qualify for reporting in discontinued operations include the disposal of a component of an entity's operations that comprises operations and cash flow that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. The Company has adopted this standard and its adoption had no significant effect on the Company's financial statements.

Intangible assets

Patents are being amortized over their remaining lives ranging from 8.5 years through 16 years.

Goodwill and Purchased Intangible Assets

Goodwill is tested for impairment on an annual basis and between annual tests in certain circumstances, and is written down when impaired in accordance with SFAS No. 142, “Goodwill and Other Intangible Assets.” For goodwill, the Company performs a two-step impairment test. In the first step, the Company compares the fair value of the reporting unit to the carrying value, including goodwill. The Company determines the fair value of the reporting unit based on a weighting of income and market approaches. If the fair value of the reporting unit exceeds the carrying value of the net assets assigned to that unit, goodwill is not impaired and no further testing is performed. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of the reporting unit, then the Company performs the second step of the impairment test in order to determine the implied fair value of the reporting unit’s goodwill. If the carrying value of a reporting unit’s goodwill exceeds its implied fair value, the Company records an impairment loss equal to the difference.

Based on the impairment tests performed, the Company recorded impairment charges for goodwill of $131,382 in fiscal 2007, related to the purchase of Scanview (Note 6). Purchased intangible assets other than goodwill are amortized over their useful lives.

-22-

Medical International Technology, Inc.

Revenue Recognition

The Company recognizes revenue when the related product is shipped to the respective customer provided that: title and risk of loss have passed to the customer; persuasive evidence of an arrangement exists; the sales price is fixed or determinable; and collectability is deemed probable.

Research and Development

Research and development expenditures are charged to operations as incurred.

Stock options

Effective July 1, 2005, the Company adopted Statement of Financial Accounting Standards (SFAS) 123(R), “Share-Based Payment,” using the modified prospective method. SFAS 123(R) establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services and requires that the compensation cost relating to share-based payment transactions be recognized in financial statements, based on the fair value of the equity or liability instruments issued, adjusted for estimated forfeitures. The Company determines the value of stock options utilizing the Black-Scholes option-pricing model. Compensation costs for share-based awards with pro rata vesting are allocated to periods on a straight-line basis.

The Company accounts for options granted to consultants in accordance with Emerging Issues Task Force (EITF) Issue 96-18, “Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services,” and SFAS 123(R).

Net Loss per Common Share

Basic earnings per share (“EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution from the exercise or conversion of securities into common stock, including stock options and warrants. For the years ended Spetember 30, 2008 and 2007, there were no dilutive effects of such securities as the Company incurred a net loss in each period. There were no outstanding options or warrants as of September 30, 2008 and 2007.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Income Taxes

The Company recognizes income tax expense based on the liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the income tax effect of temporary differences between the tax basis of assets and liabilities and their carrying values for financial reporting purposes. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities during the period. The Company has recorded a valuation allowance, which reflects the estimated amount of deferred tax assets that more likely than not will be realized.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consists principally of cash in banks and trade receivables. The Company manages this risk by maintaining all deposits in high quality financial institutions and periodically performing evaluations of the relative credit standing of the financial institutions that are considered in the Company’s investment strategy. The Company grants unsecured credit to its customers during the normal course of business and performs ongoing credit evaluations of its customers to minimize any potential loss.

Fair Value of Financial Instruments

The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable and accounts payable. Management believes that the carrying values of these assets and liabilities are representative of their respective fair values based on their short-term nature.

-23-

Medical International Technology, Inc.

New Accounting Pronouncements

In December 2007, the FASB issued SFAS No. 141(R), “Business Combinations”. This Statement replaces SFAS No. 141, Business Combinations . This Statement retains the fundamental requirements in Statement 141 that the acquisition method of accounting (which Statement 141 called the purchase method ) be used for all business combinations and for an acquirer to be identified for each business combination. This Statement also establishes principles and requirements for how the acquirer: a) recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree; b) recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase and c) determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. SFAS No. 141(R) will apply prospectively to business combinations for which the acquisition date is on or after Company’s fiscal year beginning October 1, 2009.

In December 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements”. This Statement amends ARB 51 to establish accounting and reporting standards for the noncontrolling (minority) interest in a subsidiary and for the deconsolidation of a subsidiary. It clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. The Company has not yet determined the impact, if any, that SFAS No. 160 will have on its consolidated financial statements. SFAS No. 160 is effective for the Company’s fiscal year beginning October 1, 2009.

Note 3 – Inventories

Inventories at September 30, 2008 and 2007 consist of the following:

	2008		2007
Raw materials	$	139,604	$	159,698
Work in process		23,863		21,752
Finished goods		5,992		13,376
Total	$	169,459	$	194,826

Note 4 – Research Credit Receivable

Research and development costs are charged to operations when incurred. For its research efforts in Canada, the Company receives a cash payment from the Canadian Government based upon the amount actually incurred. The Company nets the credit against related costs charged to operations. Research and development expenses are as follows:

	2008			2007
R&D Costs	$	1,802,857		$	163,712
Less Credit		( 3,158	)		( 29,418	)
	$	1,802,085		$	134,294

-24-

Medical International Technology, Inc.

Note 5 – Intangible Assets

As of September 30, 2008 the Company has net intangible assets totaling $632. Amortization expenses for the year ended September 30, 2008 and 2007 were $466 and $466, respectively. Intangible assets consist of the following:

		Gross Intangible Assets		Accumulated Amortization		Net Intangible Assets		Weighted Average Life (Years)
Patents		$2,030		$1,398		$632		8.5 through 16

Note 6 – Scanview Acquisition

On June 11, 2007, the Company completed the acquisition of all the issued and outstanding shares of 9139-2449 Quebec Inc. (dba Scanview), a related party, for 2,500,000 common shares of the Company. ScanView was a private Canadian company owned 55% by the Company’s CEO, 10% by the Company’s CFO and three other unrelated shareholders. ScanView has a unique, portable and battery operated ultrasound diagnostic medical devices, using a variety of probes for pathological and physiological evaluation of organs such as the heart, kidneys, liver, thyroid, uterus and ovaries. They serve equally well to detect kidney stones, diagnose pregnancy, visualize follicle development and carry out all other normal ultrasound diagnostic procedures.

The Company valued the common share issued at 0.07 per share or $175,000, which represented the adjusted average closing share price for the week prior and week after the closing date. The fair value of the assets acquired by the Company was approximately $321,603, consisting of cash of $819, tax credits receivable of $48,429, inventory of $67,334, equipment of $73,639 and goodwill of $131,382, and the Company assumed approximately $146,603 in liabilities, consisting of 2 notes payable agreements to a bank aggregating $52,564 (Note 12) and trade accounts payable and other accrued expenses aggregating $94,039.

During the fourth quarter of 2007, the Company determined, based on impairment testing performed, that the recorded amount of goodwill of $131,382 from the Scanview purchase was impaired. Accordingly, the Company charged off $131,382 as impairment charges of goodwill.

Note 7 – Related Party Transactions

Related party balances consist of the following at September 30, 2008 and 2007:

	2008		2007
Payable to Idee International R&D, Inc.	$	1,480,378	$	-
Payable to 2849-674 Canada, Inc.		34,637		62,045
Payable to 9117-2221 Quebec Inc.		9,306		1,005
	$	1,524,321	$	63,050

The Company has borrowed from shareholders and corporations owned by shareholders. These loans are non-interest bearing and due upon demand. In addition, the Company has advanced funds to other corporations owned by shareholders. These loans are also non-interest bearing and due upon demand.

During fiscal 2008 and effective October 1, 2007, the Company entered into a Research and Development Contract with Idee International R&D, Inc.(“Idee”), an entity owned individually by the Company’s CEO and President. Under the terms of the agreement, Idee will perform specific research and development on needle-free technologies, as defined in the agreement, from October 1, 2007 to September 30, 2009, and the Company will pay Idee $150,000 per month. The monthly charge is recorded as research and development costs on the accompanying consolidated income statement. During the year ended September 30, 2008, the Company paid Idee $319,622 under this agreement. The Company has accrued a liability to Idee of $1,480,378 under this contract.

-25-

Medical International Technology, Inc.

Note 8 – Income Taxes

Deferred income taxes are provided for the tax effects of temporary differences in the reporting of income for financial statement and income tax reporting purposes and arise principally from net operating loss carry-forwards, accrued expenses and basis differences in fixed assets.

The Company’s effective tax rate differs from the Federal statutory rates due to the valuation allowance recorded for the unused net operating loss carry-forwards deferred tax asset. The company has operating losses of $9,333,413, which can be used to reduce future taxable income. An allowance has been provided for by the Company which reduced the tax benefits accrued by the Company for its net operating losses to zero, as it cannot be determined when, or if, the tax benefits derived from these operating losses will materialize.

Note 9 – Stockholders' Equity (Deficit)

Issuance of Common Stock

Year Ended September 30, 2008

There were no common stock issuances during the year ended September 30, 2008.

Year ended September 30, 2007

For the year ended September 30, 2007, the Company issued an aggregate of 16,192,546 shares of its common stock for acquisition, consulting and legal services, debts and private placements. The value assigned to these shares at the market value, aggregated $1,170,558 and is more fully described below.

For the 1st quarter ended December 31, 2006, the Company issued 779,400 shares of its common stock for consulting and legal services. The value assigned to these shares totaled $163,596 the market value of the services rendered, which were charged to operations.

For the second quarter ended March 31, 2007, the Company issued 63,750 shares of its common stock for consulting and legal services. The value assigned to these shares totaled $10,200 the market value of the services rendered, which were charged to operations.

For the third quarter ended June 30, 2007, the Company issued 3,721,310 shares of its common stock for consulting and legal services. The value assigned to these shares totaled $195,705 the market value of the services rendered, which were charged to operations.

For the fourth quarter ended September 30, 2007, the Company issued 4,954,368 shares of its common stock for consulting and legal services. The value assigned to these shares totaled $267,488 the market value of the services rendered, which were charged to operations.

For the 1st quarter ended December 31, 2006, the Company issued 72,000 shares of its common stock for private placements. The value assigned to these shares totaled $14,993.

For the second quarter ended March 31, 2007, the Company issued 200,000 shares of its common stock for private placements. The value assigned to these shares totaled $200,000.

For the third quarter ended June 30, 2007, the Company issued 2,500,000 shares of its common stock for acquisition of SCANVIEW. The value assigned to these shares totaled $175,000.

For the fourth quarter ended September 30, 2007, the Company issued 3,920,985 shares of its common stock for debts. The value assigned to these shares totaled $293,490.

Preferred Stock

As of September 30, 2008, there was no preferred stock outstanding. Dividend features and voting rights are at the discretion of the Board of Directors without the requirement of shareholder approval.

Outstanding Options

Effective October 1, 2006 the company entered into a Consulting services Agreement with Geoffrey Armstrong engaging him as an administrative manager for the company. As part of the agreed compensation Mr. Armstrong was granted 750,000 options to purchase Common shares at a price of $0.40 per share. These options expired on October 3, 2007.

-26-

Medical International Technology, Inc.

As of September 30, 2008, there are no options outstanding to purchase shares of the Company’s common stock.

Outstanding Warrants

During the year ended September 30, 2008, 4,224,000 Series A Stock Purchase Warrants and 3,224,000 Series B Stock Purchase warrants expired. The Stock Purchase Warrants had been issued in connection with private placements completed in fiscal 2006.

As of September 30, 2008, there are no warrants outstanding to purchase shares of the Company’s common stock.

Note 10 –Operating Leases

The Company leases its office and warehouse space under an operating lease that expires on October 31, 2009. Rent expense for the year ended September 30, 2008 was approximately $33,300.

Future minimum lease commitments pertaining to the lease expire as follow:

Year ended
September 30 2009		33,300
September 30, 2010		2,775
	$	36,075

Note 11– Unearned Income

Unearned income consists of the following at September 30, 2008 and 2007:

	2008		2007
Deposits from customers and distributors	$	53,782	$	7,494
Nonrefundable Distribution Rights Deposit		1,300,000		-
Total unearned income	$	1,353,782	$	7,494

On November 1 st , 2007, the Company received a Non-Refundable deposit of $1,300,000 for the worldwide rights to market and sells all Medical International Technology Inc.’s present and future Needle-Free Jet-Injectors for the human and animal markets. This deposit is part of an agreement under negotiation, and will be disclosed when finalized, which the Company expects to occur in fiscal 2009. The Company has recorded the deposit as unearned income until such time as a final agreement is reached, at which time the deposit will be earned as income over the estimated contractual life of the final agreement.

Note 12 –Notes Payable

Long-term debt consists of the following at September 30, 2008 and 2007:

	2008			2007

Note payable to a bank, bearing interest at prime plus 2.5%,
secured by equipment, due July 21, 2010	$	15,097		$	22,040
Note payable to a bank, bearing interest at prime plus 3%,
secured by equipment, due August 28, 2008		-			25,375
Note payable to an individual, unsecured and due on demand		-			250,000
Total long-term debt	$	15,097		$	297,415
Current portion of long-term debt		(8,237	)		(283,154	)
Total long-term debt, net	$	6,860		$	14,261

Schedule maturities of long-term debt are as follows:

Year ended September 30, 2009	$	8,237
Year ended September 30, 2010		6,860
Total	$	15,097

-27-

Medical International Technology, Inc.

Note 13 –Contingencies

Legal Proceedings

From time to time, the Company is named in legal actions in the normal course of business. In the opinion of management, the outcome of these matters, if any, will not have a material impact on the financial condition or results of operations of the Company.

-28-

Medical International Technology, Inc.

Item 8. Changes In / Disagreements with Accountants on Accounting/Financial Disclosure

None

Item 8A. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our Principal Executive Officer and our Principal Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report (September 30, 2008), as is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Our disclosure controls and procedures are intended to ensure that the information we are required to disclose in the reports that we file or submit under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and (ii) accumulated and communicated to our management, including the Principal Executive Officer and Principal Financial Officer to allow timely decisions regarding required disclosures.

Based on that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that, as of the end of the period covered by this Annual Report, our disclosure controls and procedures were effective.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events.

Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over our financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our Principal Executive Officer and Principal Financial Officer concluded that, as of the end of the period covered by this Annual Report, our internal control over financial reporting was effective.

This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by our independent registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management's report in this Annual Report.

Changes in Internal Control Over Financial Reporting

During our most recent fiscal quarter, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

-29-

Medical International Technology, Inc.

Item 8B. Other Information

None.

Item 9. Directors, Executive Officers, Promoters and Control Persons

The directors and officers are as follows:

NAME POSITION (S) TENURE

Karim Menassa Chairman, President, Director June 27, 2002 to present

Michel Bayouk Secretary, Director June 27, 2002 to present

Mr. Karim Menassa , age 57, serves as the President of Medical International Technology, Inc. Mr. Menassa also serves as a member of the Board of Directors of Medical International Technology, Inc. Mr. Menassa has developed many state-of-the-art, efficient and reliable devices, and has marketed various medical devices in more than 60 countries. Mr. Menassa obtained a degree in Precision Mechanics Design from the Instituto Salesiano Don Bosco in

Cairo, Egypt.

Mr. Michel Bayouk , age 62, serves as the Secretary of Medical International Technology, Inc. Mr. Bayouk also serves as a member of the Board of Directors of Medical International Technology, Inc. Mr. Bayouk is a Chartered Accountant and has been involved in financial auditing since 1970.

The directors shall be elected at an annual meeting of the stockholders and except as otherwise provided within the Bylaws of Medical International Technology, Inc., as pertaining to vacancies, shall hold office until his successor is elected and qualified.

Although Medical International Technology, Inc. does not have a separate Audit Committee and these functions are performed by the entire board, the board of directors of Medical International Technology, Inc. has determined that for the purpose of and pursuant to the instructions of item 401(e) of regulation S-B titled Audit Committee Financial Expert, Mr. Michel Bayouk possesses the attributes of an Audit committee financial expert. Mr. Bayouk is a board member of Medical International Technology, Inc. Mr. Bayouk is not independent as defined by item 401(e) (ii) of regulation S-B. He receives compensation for services rendered to Medical International Technology, Inc. directly or through services rendered by related companies owned or controlled by him.

Board of Director Meetings and Committees

The Board of Directors held no meetings during the year ended September 30, 2008, but conducted board activities through unanimous consent board resolutions in lieu of meetings.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934 requires the company’s directors and officers, and persons who own more than ten-percent (10%) of the company’s common stock, to file with the Securities and Exchange Commission reports of ownership on Form 3 and reports of change in ownership on Forms 4 and 5. Such officers, directors and ten-percent stockholders are also required to furnish the company with copies of all Section 16(a) reports they file. Based solely on its review of the copies of such forms received by the company and on written representations from certain reporting persons, the company believes that all Section 16(a) reports applicable to its officers, directors and ten-percent stockholders with respect to the fiscal year ended September 30, 2008 were filed.

Code of Ethics

We have adopted a code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The code of ethics is designed to deter wrongdoing and to promote:

•	Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

•	Full, fair, accurate, timely, and understandable disclosure in reports and documents that we file with, or submit to, the SEC and in other public communications made by MIT;

-30-

Medical International Technology, Inc.

•	Compliance with applicable governmental laws, rules and regulations;

•	The prompt internal reporting of violations of the code to an appropriate person or persons identified in the code; and

•	Accountability for adherence to the code.

We will provide to any shareholder, upon request, a copy of our code of ethics. Any such request should be directed to our corporate secretary at 1872 Beaulac, Ville Saint Laurent, Montreal, Quebec, Canada HR4 2E9.

Item 10. Executive Compensation

Compensation Summary

SUMMARY COMPENSATION TABLE

		Annual Compensation						Award(s)				Payouts
								Restricted		Securities
						Other Annual		Stock		Underlying		LTIP		All Other
		Salary		Bonus		Compensation		Award(s)		Options/SARs		Payouts		Compensation
Position	Year	$		$		$		$			(#)	$		$

Karim	2008		0		0		0		0		0		0		0
Menassa	2007		0		0		106,338		0		0		0		0
President	2006		0		0		49,538		0		0		0		0
and Director

Michel	2008		0		0		0		0		0		0		0
Bayouk	2007		0		0		0		0		0		0		0
Secretary	2006		0		0		0		0		0		0		0
and Director

Notes:

1.	On April 27, 2007 the Company issued 761,904 restricted common shares at a price of $0.0525 per share to Idee International R & D Inc., a company owned 100% by 2849674 Canada Inc. for a debt conversion of $40,000. Karim Menassa, our President and Director control the entity 2849674 Canada Inc.

2.	On April 27, 2007 the Company issued 1,523,809 restricted common shares at a price of $0.0525 per share to 2849674 Canada Inc. for a debt conversion of $40,000. Karim Menassa, our President and Director control the entity 2849674 Canada Inc.

3.	On April 27, 2007 the Company issued 1,391,047 restricted common shares at a price of $0.0525 per share to 9117-2221 Quebec Inc., for a debt conversion of $32,000. Michel Bayouk, our Financial Officer and Director control the entity 9117-2221 Quebec Inc.

ScanView was a private Canadian company owned by Karim Menassa, our CEO and Director, owning 55% of Scanview, Michel Bayouk, our CFO and Director, owning 10% of Scanview and three other unrelated shareholders. On July 17, 2007 the Company issued 3,416,667 restricted common shares at a price of $0.06 per share to Idee International R & D Inc., a company owned 100% by 2849674 Canada Inc. for a debt conversion of $205,000. Karim Menassa, our President and Director control the entity 2849674 Canada Inc.

6.	On July 17, 2007 the Company issued 1,733,333 restricted common shares at a price of $0.06 per share to 2849674 Canada Inc. for a debt conversion of $104,000. Karim Menassa, our President and Director control the entity 2849674 Canada Inc.

7.	On August 20, 2007 the Company issued 841,750 restricted common shares at a price of $0.03 per share to Maurice Menassa for services rendered of US$ 25,252.50.

8.	On August 24, 2007 the Company issued 1,747,684 restricted common shares at a price of $ 0.0262 per share to 2849674 Canada Inc. for services rendered of US$ 45,789.33. Karim Menassa, our President and Director control the entity 2849674 Canada Inc.

9.	On August 24, 2007 the Company issued 503,926 restricted common shares at a price of $ 0.0262 per share to IDEE INT’L R&D Inc. for a debt conversion of US$ 13,202.88. Karim Menassa, our President and Director control the entity 2849674 Canada Inc.

10.	On August 24, 2007 the Company issued 631,106 restricted common shares at a price of $ 0.0262 per share to 2849674 Canada Inc. for services rendered of US$ 16,535.00. Karim Menassa, our President and Director control the entity 2849674 Canada Inc.

-31-

Medical International Technology, Inc.

As of September 30, 2008, the Company had no group life; health, hospitalization, medical reimbursement or relocation plans in effect. Further, we had no pension plans or plans or agreements which provide compensation on the event of termination of employment or change in control of us.

We do not pay members of our Board of Directors any fees for attendance or similar remuneration or reimburse them for any out-of-pocket expenses incurred by them in connection with our business.

Compensation of Directors

There was no compensation paid to any directors of Medical International Technology, Inc. as director’s fees.

Employment Agreements

No formal employment agreements exist with any officer or employee.

Long-Term Incentive Plan

The Company has a stock compensation plan under which directors are authorized to grant incentive stock options, to a maximum of one million (1,000,000) of the issued and outstanding shares, to directors, employees and consultants of the Company. The plan provides both for the direct award or sale of shares and for the grant of options to purchase shares.

Item 11. Security Ownership of Certain Beneficial Owners and Management

The following table sets forth, all individuals known to beneficially own 5% or more of the Company's common stock, and all officers and directors of the registrant, with the amount and percentage of stock beneficially owned as of September 30, 2008:

Name and Address	Amount and Nature
Of Beneficial Holder	of Beneficial Ownership	Percentage

Karim Menassa	14,533,179 shares		53.7%
President, Director
1872 Beaulac, Ville Saint-Laurent
Montreal, Quebec, Canada HR4 2E7

Michel Bayouk	3,281,183 shares		12.1%
Secretary, Director
1872 Beaulac, Ville Saint-Laurent
Montreal, Quebec, Canada HR4 2E9

Officers and Directors as a Group	17,814,362 shares		65, 8%

Total issued and outstanding as of September 30, 2008 was 27,058,663 shares.

Notes:

Karim Menassa directly holds common shares of Medical International Technology, Inc., indirectly through 2849674 Canada, Inc., which is controlled by Karim Menassa, and indirectly through Idee R&D International, Inc.’s, which is controlled by Karim Menassa, and also indirectly through 9162-9725 Quebec Inc., witch is also controlled by Karim Menassa.

Michel Bayouk directly holds common shares of Medical International Technology, Inc., indirectly through 1065029 Canada, Inc. which is controlled by Michel Bayouk, indirectly through 9117-2221 Quebec, Inc. which is 100% owned by Michel Bayouk, indirectly through Dynagroup Services, Inc., a company in which Michel Bayouk maintains an interest, and also indirectly through 9162-9725 Quebec Inc. which Michel Bayouk maintains an interest.

All ownership is beneficial and of record except as specifically indicated otherwise. Beneficial owners listed above have sole voting and investment power with respect to the shares shown unless otherwise indicated.

-32-

Medical International Technology, Inc.

Item 12. Certain Relationships and Related Transactions

None

Item 13. Exhibits

31.1	Certifications of the Chief Executive Officer required by Rule 13A-14 or Rule 15D-14 Under the Securities Exchange Act of 1934, As Amended

31.2	Certifications of the Chief Financial Officer required by Rule 13A-14 or Rule 15D-14Under the Securities Exchange Act of 1934, As Amended

32.1	Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2	Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Item 14. Principal Accountant Fees and Services

(1)	Audit Fees

The aggregate fees billed for each of the last two fiscal years for professional services rendered by the principal accountant for the audit of the registrant's annual financial statements and review of financial statements included in the registrant's Form 10-QSB or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for the fiscal years ending September 30, 2008 and 2007 were: $22,500 and $22,500 respectively.

(2)	Audit-Related Fees

The aggregate fees billed in each of the last two fiscal years for assurance and related services by the principal accountant that are reasonably related to the performance of the audit or review of the registrant's financial statements and are not reported under item (1) for the fiscal years ending September 30, 2008 and 2007 were: $0 and $0, respectively.

The nature of the services comprising the fees herein disclosed are: none provided .

(3)

Tax Fees

The aggregate fees billed for professional services rendered by the principal accountant for tax compliance, tax advice, and tax planning for the fiscal years ending September 30, 2008 and 2007 were: $0 and$0, respectively.

The nature of the services comprising the fees herein disclosed are: none provided

(4)	All Other Fees

No aggregate fees were billed for professional services provided by the principal accountant, other than the services reported in items (1) through (3) for the fiscal years ending September 30, 2008 and 2007.

(5)	Audit Committee

The registrant's Audit Committee, or officers performing such functions of the Audit Committee, have approved the principal accountant's performance of services for the audit of the registrant's annual financial statements and review of financial statements included in the registrant's Form 10-QSB or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for the fiscal year ending September 30, 2008. Audit-related fees, tax fees, and all other fees, if any, were approved by the Audit Committee or officers performing such functions of the Audit Committee.

(6)	Work Performance by others

None

-33-

Medical International Technology, Inc.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Medical International Technology, Inc.

Date: December 10, 2008	By:	/s/ Karim Menassa
		Karim Menassa
		President and Principal Executive Officer


Date: December 10, 2008	By:	/s/ Michel Bayouk
		Michel Bayouk
		Secretary and Principal Accounting Officer

-33-

Medical International Te... (CE) (USOTC:MDLH)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Haga Click aquí para más Gráficas Medical International Te... (CE).

Medical International Te... (CE) (USOTC:MDLH)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

MDLH Medical International Technology Inc (CE)

Noticias sobre Medical Intl Tech (OTC) MDLH

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

MDLH Medical International Technology Inc (CE)

Noticias sobre Medical Intl Tech (OTC) MDLH

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

BLACK FRIDAY

Ahorra hasta 60%* en Forex

1 año 40%, 2 años 40% y *3 años 60%